Sign In
Buy HOOK
$1.15
+0 (+0%)
At Close: Jun 03, 2026
Hookipa: Speculative Biotech With Key Catalysts In 2022
09:02am, Tuesday, 29'th Mar 2022
Several data readouts of HB-200 alone and in combination with KEYTRUDA for treatment of HPV16+ HNSCC patients are expected in 2022.
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Misses Revenue Estimates
12:15pm, Thursday, 24'th Mar 2022 Zacks Investment Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -22.64% and 9.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) CEO Joern Aldag on Q4 2021 Results - Earnings Call Transcript
12:15pm, Thursday, 24'th Mar 2022
HOOKIPA Pharma Inc. (HOOK) CEO Joern Aldag on Q4 2021 Results - Earnings Call Transcript
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto
Novartis AG (NYSE: NVS) said the U.S.
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Misses Revenue Estimates
09:47am, Thursday, 24'th Mar 2022
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -22.64% and 9.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022
11:00am, Thursday, 17'th Mar 2022 GlobeNewswire Inc.
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary ar
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022
07:00am, Thursday, 17'th Mar 2022
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav
Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for
08:00pm, Thursday, 10'th Mar 2022 Zacks Investment Research
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for
04:33pm, Thursday, 10'th Mar 2022
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology
09:51pm, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
NEW YORK and VIENNA, Austria, March 08, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary ar
HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology
09:51pm, Tuesday, 08'th Mar 2022 GlobeNewswire
NEW YORK and VIENNA, Austria, March 08, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that preclinical, translational, and clinical biomarker data from its oncology pipeline have been selected for four poster presentations at the 2022 American Association for Cancer Research Annual Meeting (AACR), taking place April 8-13.
NEW YORK and VIENNA, Austria, March 08, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
03:05pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
12:50pm, Wednesday, 02'nd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endome
HOOKIPA Pharma slumps 15% on pricing $75M stock and preferred stock offering
12:19pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
HOOKIPA Pharma (HOOK) trades 15.1% down premarket after pricing its underwritten public offering of 21.7M shares and 15.8K shares of its non-voting Series A-1 convertible…
